Diagnosis and management of resistant hypertension: state of the art
Open accessThe DOI matches its Crossref record; 137 of the 138 references it cites were found in a registry or an index.
Abstract
Resistant hypertension is defined as a lack of ambulatory blood pressure response to optimized medical treatment after exclusion of secondary hypertension in patients who are fully adherent to antihypertensive therapy. Patients with resistant hypertension are at high risk of complications, particularly cardiovascular events, and optimization of medical treatment remains the cornerstone of their management. Such optimization should be based on simple algorithms and include the use of aldosterone antagonists. The available data from clinical trials do not support the use of device-based approaches such as renal denervation, baroreflex activation therapy or arteriovenous anastomosis for the treatment of resistant hypertension in the majority of patients. Therefore, device treatment remains a last-resort for patients with truly resistant hypertension in the context of clinical research in highly skilled tertiary referral centres. Future research should focus on improving understanding of the intrinsic (physiological and psychological factors) and extrinsic (environmental stressors) mechanisms that contribute to a lack of response to blood-pressure-lowering drugs in adherent patients. The use of biomarkers to identify patients with early target organ damage and new technologies, such as renal nerve stimulation, to predict blood pressure responses to renal denervation could aid the selection of patients who might benefit from device therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Poor adherence to antihypertensive treatment correlates with the magnitude of BP elevation and is an indicator of poor prognosis in hypertensive patients. 78-81”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [79]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Retracted: Predictive Validity of a Medication Adherence Measure in an Outpatient Setting
Morisky, D. E., Ang, A., Krousel‐Wood, M., & Ward, H. J. (2008) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.07572.x · Cited by 2,877
Retracted(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Forouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Gakidou, E., Afshin, A., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulle, A. M., Abera, S. F., Aboyans, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32366-8 · Cited by 2,406
Calhoun, D. A., Jones, D., Textor, S., Goff, D. C., Murphy, T. P., Toto, R. D., White, A., Cushman, W. C., White, W., Sica, D., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.189141 · Cited by 2,237
A Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
O'Brien, E., Asmar, R., Beilin, L., Imai, Y., Mallion, J.-M., Mancia, G., Mengden, T., Myers, M., Padfield, P., Palatini, P., et al. (2003) · Journal of Hypertension · doi:10.1097/00004872-200305000-00001 · Cited by 1,655
Self-citation
Cited by
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132
“Background Resistant hypertension is defined as seated office BP >140/ 90mmHg in a patient treated with three or more antihypertensive medications at optimal (or maximally tolerated) doses including a diuretic and after excluding pseudoresistance (poor BP measurement technique, white-coat effect, nonadherence, and sub…”
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
Self-citation2020 International Society of Hypertension global hypertension practice guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002453 · Cited by 1,283
“Background Resistant hypertension is defined as seated office BP >140/90 mm Hg in a patient treated with three or more antihypertensive medications at optimal (or maximally tolerated) doses including a diuretic and after excluding pseudoresistance (poor BP measurement technique, white coat effect, nonadherence and sub…”
Resistant Hypertension: Novel Insights
Lamirault, G., Artifoni, M., Daniel, M., Barber‐Chamoux, N., & Nantes University Hospital Working Group on Hypertension (2019) · Current Hypertension Reviews · doi:10.2174/1573402115666191011111402 · Cited by 104
Zhang, Z., Yu, Y., Asayama, K., Hansen, T. W., Maestre, G. E., & Staessen, J. A. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.12858 · Cited by 33
Self-citation
Metadata
- Authors
- Wei, F.-F., Zhang, Z.-Y., Huang, Q.-F., & Staessen, J. A.
- Affiliations
- KU Leuven (BE)
- Shanghai First People's Hospital (CN)
- Shanghai Jiao Tong University (CN)
- Maastricht University (NL)
- Corresponding author
- Staessen, Jan A.
- Venue
- Nature Reviews Nephrology
- Published
- 2018-04-26
- Volume
- 14
- Issue
- 7
- Pages
- 428-441
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- OpenAlex
- W2802817226
- Cited by
- 39
- References
- 138
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 11 · 2018: 2
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Lirias (submittedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- European Commission (713601, 2011-294713-EPLORE, 305507)
- Vlaamse regering
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- resistant hypertension, mineralocorticoid receptor antagonists, renal denervation, baroreflex activation therapy, arteriovenous anastomoses, medication adherence, secondary hypertension, cardiovascular risk, target organ damage, biomarkers, renal nerve stimulation
- MeSH terms
- Mineralocorticoid Receptor Antagonists, Amiloride, Animals, Antihypertensive Agents, Arteriovenous Shunt, Surgical, Blood Pressure Determination, Carotid Arteries, Carotid Body, Coronary Vasospasm, Electric Stimulation Therapy, Humans, Hypertension, Pressoreceptors, Renal Artery, Spironolactone, Sympathectomy, Baroreflex, Medication Adherence, Epithelial Sodium Channel Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis and management of resistant hypertension: state of the art. https://app.cochat.ai/papers/10.1038/s41581-018-0006-6
- The paper
- Wei, F.-F., Zhang, Z.-Y., Huang, Q.-F., & Staessen, J. A. (2018). Diagnosis and management of resistant hypertension: state of the art. Nature Reviews Nephrology. https://doi.org/10.1038/s41581-018-0006-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.